A Four-Part, Phase 3, Randomized, Double-Blind, Placebo- Controlled, Four-Arm, Discontinuation Study to Evaluate the Efficacy and Safety of Subcutaneous Injections of BMN 165 Self-Administered by Adults With Phenylketonuria (PKU)

Trial Profile

A Four-Part, Phase 3, Randomized, Double-Blind, Placebo- Controlled, Four-Arm, Discontinuation Study to Evaluate the Efficacy and Safety of Subcutaneous Injections of BMN 165 Self-Administered by Adults With Phenylketonuria (PKU)

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Sep 2017

At a glance

  • Drugs Pegvaliase (Primary)
  • Indications Phenylketonuria
  • Focus Adverse reactions; Registrational
  • Acronyms PRISM-2; Prism302
  • Sponsors BioMarin Pharmaceutical
  • Most Recent Events

    • 14 Sep 2017 According to a BioMarin Pharmaceutical media release, the US FDA has provided the company with the "Day-74" filing communication for its Biologics License Application for pegvaliase to reduce blood phenylalanine levels in adult patients with phenylketonuria who have uncontrolled blood phenylalanine levels on existing management. The FDA advised that, it is not planning to hold an advisory committee meeting for the review of the application.
    • 05 Sep 2017 According to a BioMarin Pharmaceutical media release, data will be presented at the 13th International Congress of Inborn Errors of Metabolism (ICIEM) 2017.
    • 29 Aug 2017 According to a BioMarin Pharmaceutical media release, the US FDA accepted for Priority Review the BLA for pegvaliase to reduce blood phenylalanine (Phe) levels in adult patients with phenylketonuria (PKU) who have uncontrolled blood Phe levels on existing management. The PDUFA action date is February 28, 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top